The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company’…
Tradjenta
New Studies Evaluating Tradjenta, Type 2 Diabetes Treatment
Eli Lilly and Boehringer Ingelheim presented results from two randomized phase 3 clinical trials and a post-hoc analysis…
Tradjenta Proves Effective in African Americans with Type 2 Diabetes
Boehringer Ingelheim and Eli Lilly announced results of a Phase 3 study in African American adults that shows taking Tra…
Jentadueto, Lilly’s New Type 2 Diabetes Drug is Now Available in the US
Eli Lilly and Boehringer Ingelheim have announced Jentadueto tablets are now available by prescription in pharmacies acr…
Lilly’s New Type 2 Diabetes Drug Receives EU Approval
The new type 2 diabetes drug Trajenta (linagliptin 5 mg film-coated tablets) received Marketing Authorization from the …
Type 2 Diabetes Drug, Linagliptin, Receives Positive Opinion From EMA and CHMP
The European Medicines Agency's (EMA) medicinal committee issued an opinion recommending the approval of linagliptin, 5 …
New Type 2 Diabetes Treatment Tradjenta Now Available in U.S. Pharmacies
The new type 2 diabetes drug Tradjenta (linagliptin) is now available by prescription in pharmacies across the United S…
FDA Approves Tradjenta for Treatment of Type 2 Diabetes
The U.S. Food and Drug Administration (FDA) has approved Boehringer Ingelheim and Eli Lilly's type 2 diabetes drug Tradj…
Boehringer Ingelheim Presents New Studies at EASD Annual Meeting
This week at the 46 th Annual Meeting of the European Association for the Study of Diabetes (EASD) Boehringer Ingelheim …
